REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,752.50
Bid: 1,752.00
Ask: 1,752.50
Change: 19.00 (1.10%)
Spread: 0.50 (0.029%)
Open: 1,736.00
High: 1,752.50
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: UK Banks Fall After Barclays Posts Profit Drop

Thu, 18th Feb 2021 12:12

(Alliance News) - Stock prices in London continued to slide at midday on Thursday amid concern that a revival in inflation might hold back economic recovery, while UK banks were lower after Barclays annual results disappointed investors.

London's blue-chip index was down 51.34 points, or 0.7%, at 6,659.56. The FTSE 250 index was down 44.92 points, or 0.3%, at 21,103.97, and the AIM All-Share index was flat at 1,222.95.

The Cboe UK 100 index was down 0.1% at 662.81 points. The Cboe 250 was down 0.1% at 18,662.02. The Cboe Small Companies was trailing, down 0.9% at 1,212.36.

The CAC 40 index in Paris was down 0.4% and Frankfurt's DAX 30 was 0.1% lower.

"It has been a lacklustre morning so far as traders continue to be a little cautious about US government bond yields, even though the closely watched 10 year yield has dipped. Like with yesterday, there are minor concerns that US yields could spike due to chatter that inflation is set to rise because of all the various stimulus packages. Upward moves in yields is likely to spark speculation about higher interest rates - something that central banks don't even want to think about for the foreseeable future," said CMC Markets analyst David Madden.

In the FTSE 100, Ashtead Group was the best performer, up 3.1% after Goldman Sachs started coverage on the equipment rental firm with a Buy rating, saying the equipment rentals firm offers strong medium-term growth potential, despite the stock trading at record highs.

"We think there is room for further re-rating as we believe we are at the beginning of an upgrade cycle supported by improving cyclical trends," analysts at the US bank said.

At the other end of the large-caps, Smith & Nephew was still the worst performer, 5.1% lower, but recouping some of its earlier losses. The medical devices maker reported a fall in annual earnings, as the coronavirus pandemic caused elective surgical procedures to be put on hold.

For 2020, revenue was down 11% to USD4.56 billion from USD5.14 billion in 2019, and trading profit fell sharply to USD683 million from USD1.17 billion. The company declared a full-year dividend of 37.5 US cents per share, unchanged from 2019.

Looking ahead to 2021, Smith & Nephew said its outlook reflects the likely continuation of Covid-19 effects during the first half of 2021 and the uncertainty regarding the timing and pace of recovery.

Imperial Brands, GlaxoSmithKline, BP and Royal Dutch Shell 'A' and 'B' shares were down 5.0%, 3.0%, 2.4%, 2.3% and 2.2% respectively. The stocks went ex-dividend, meaning new buyers no longer qualify for the latest payout.

Shell had said Wednesday it has agreed to sell Duvernay shale light oil assets in Canada to Crescent Point Energy. Toronto-listed Crescent will pay USD707 million for the assets, USD550 million in cash and USD157 million worth of shares in the company.

Shares in UK banks were lower after Barclays kicked off sector earnings season. NatWest Group reports on Friday and Lloyds Banking Group on Wednesday next week.

NatWest was 2.5% lower. The Financial Times reported that the UK state-backed lender is gearing up to gradually withdraw from the Republic of Ireland, with the aim of freeing up capital and moving completely to the UK market.

Lloyds was off 3.8%.

Barclays was down 4.7% after reporting a drop in annual earnings - with profit falling by almost a third in 2020.

However, Barclays said it will resume dividend payments after the Bank of England lifted its ban on shareholder distributions in December.

For 2020, Barclays posted net income of GBP21.77 billion, up 1% from GBP21.63 billion in 2019, as net interest income fell 14% to GBP8.12 billion from GBP9.41 billion.

Barclays booked GBP4.84 billion in credit impairments in 2020, more than doubled from GBP1.91 billion in 2019.

Pretax profit sank 30% to GBP3.07 billion from GBP4.36 billion. However, the figure beat company-compiled consensus which forecast pretax profit of GBP2.81 billion.

Barclays declared a dividend of 1.0 pence for 2020, down from 3.0p paid in 2019. In addition, Barclays said it intends to initiate a share buyback of up to GBP700 million, which is expected to commence in the first quarter of 2021.

"On the face of it you might have expected a round of applause for Barclays fourth-quarter results which were significantly better than forecast and came with the extra cherry of a reinstated dividend, bolstered by a share buyback. Instead the company got the cold shoulder from the market as attention was drawn by large provisions on Covid-related bad debt and a warning of a continuing impact through the course of 2021," said AJ Bell's Russ Mould.

"While allowing banks to pay dividends for the year just gone, the regulator has stipulated that any dividends for 2021 have to be accrued rather than doled out, at least until it's had a chance to reassess the position the economy and financial situation is in over the summer. In other words there's no absolute guarantee the usual first-half dividend will be paid,'' Mould added.

The dollar was lower against major counterparts after dovish meeting minutes from the US Federal Reserve. The pound was quoted at USD1.3945 at midday Thursday, up sharply from USD1.3845 at the London equities close Wednesday.

The euro was priced at USD1.2070, higher against USD1.2036. Against the yen, the dollar was trading at JPY105.64, down from JPY105.82.

The US economy is "still far" from the Fed's goals, the minutes released on Wednesday showed, and it is likely to take "some time" before further progress towards the central bank's employment and inflation targets is achieved.

Analysts at ActivTrades said: "After gaining ground to other major currencies during the first half of the week, the US dollar is on the back foot during the start of Thursday's trading session. This change in dynamic came after the publication of the minutes for the Federal Reserve's last meeting, where it became clear that despite the central bank's optimistic expectations for economic growth in 2021, it has no intention to review its accommodative monetary policy or purchase program.

"The topic of inflation has recently been trending amongst investors, with many selling low coupon bonds and driving a rise in yields and subsequently increasing dollar demand, as they moved to price in a potential change of stance from the Fed. However, the Fed has no such concerns and, according to the minutes published yesterday, appears determined to maintain its current course of very low interest rates and large bond purchases, which creates scope for further dollar weakness.''

Brent oil was quoted at USD64.56 a barrel Thursday at midday, up sharply from USD63.53 late Wednesday, as US refining and extraction capacity remains shuttered due to deadly wintry conditions in Texas. The North Sea benchmark had breached the USD65 mark for the first time in over a year in early trade. The US benchmark WTI spot price was quoted USD61.45, higher against USD60.39.

Texas Governor Greg Abbott directed the Lone Star state's natural gas providers not to ship outside the state until Sunday and asked the state energy regulator to enforce the export ban.

"Oil prices rose to fresh 13-month highs as traders bet shut-ins in Texas will affect oil producers and refiners for a while longer. It's estimated that US crude output is down by as much as 3.5 million barrels per day as freezing temperatures and power outages have hit the Permian Basin," said Markets.com analyst Neil Wilson.

Gold was trading at USD1,786.25 an ounce, higher versus USD1,774.53 at the London equities close on Wednesday.

US stock market futures were pointed to a lower open as US lawmakers open a hearing Thursday seeking answers on the recent stock market frenzy that caused dizzying moves in the value of little-known shares and prompted calls for tougher Wall Street regulations.

The Dow Jones Industrial Average was called down 0.3%, the S&P 500 down 0.5% and the Nasdaq Composite down 0.8%.

The House Financial Services Committee was to hear from witnesses playing a role in the volatility affecting video game retailer GameStop and other companies in recent weeks. The unprecedented volatility prompted calls for regulators to review the role of social media, hedge funds and trading platforms which may manipulate the market.

In prepared testimony, Robinhood CEO Vladimir Tenev defended the actions of his company which enables free trades to small investors.

"Any allegation that Robinhood acted to help hedge funds or other special interests to the detriment of our customers is absolutely false and market-distorting rhetoric," Tenev said.

In the economic calendar for Thursday, there is US initial jobless claims at 1330 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.